MS drug trial halted after failing to lower nerve damage

NCT ID NCT05630547

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an oral drug called SAR443820 in 174 adults with multiple sclerosis (MS) to see if it could lower a marker of nerve damage in the blood. The trial was stopped early because the drug did not meet its main goal of reducing that marker. Participants were followed for up to 96 weeks, but the study ended before completion.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING - REMITTING MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis primary progressive multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Show contact details

Locations

Investigational Site Number : 0560001

Brussels, BE-1200, Belgium
Investigational Site Number : 0560002

Ghent, 9000, Belgium
Investigational Site Number : 0560003

Overpelt, 3900, Belgium
Investigational Site Number : 1000001

Sofia, 1407, Bulgaria
Investigational Site Number : 1000002

Sofia, 1431, Bulgaria
Investigational Site Number : 1000003

Sofia, 1680, Bulgaria
Investigational Site Number : 1240001

Gatineau, Quebec, J8Y 1W2, Canada
Investigational Site Number : 1240002

Ottawa, Ontario, K1H 8L6, Canada
Investigational Site Number : 1240003

Lévis, Quebec, G6W0M5, Canada
Investigational Site Number : 1240004

Toronto, Ontario, M5B 1W8, Canada
Investigational Site Number : 1520001

Santiago, Reg Metropolitana de Santiago, 8380456, Chile
Investigational Site Number : 1560001

Tianjin, 300052, China
Investigational Site Number : 1560002

Shanghai, 200040, China
Investigational Site Number : 1560003

Chengdu, 610041, China
Investigational Site Number : 1560004

Xi'an, 710038, China
Investigational Site Number : 2500001

Paris, 75013, France
Investigational Site Number : 2500002

Nice, 06001, France
Investigational Site Number : 2500003

Strasbourg, 67098, France
Investigational Site Number : 2500004

Caen, 14033, France
Investigational Site Number : 2760002

Würzburg, 97074, Germany
Investigational Site Number : 3800001

Pozzilli, Isernia, 86077, Italy
Investigational Site Number : 3800002

Milan, 20132, Italy
Investigational Site Number : 3800003

Milan, 20133, Italy
Investigational Site Number : 3800005

Cagliari, 09126, Italy
Investigational Site Number : 6160001

Krakow, 31-503, Poland
Investigational Site Number : 6160002

Katowice, Silesian Voivodeship, 40-571, Poland
Investigational Site Number : 6160004

Plewiska, Greater Poland Voivodeship, 62-064, Poland
Investigational Site Number : 6160005

Katowice, Silesian Voivodeship, 40-686, Poland
Investigational Site Number : 6160006

Zabrze, 41-800, Poland
Investigational Site Number : 7240001

Barcelona, Barcelona [Barcelona], 08035, Spain
Investigational Site Number : 7240002

Seville, Andalusia, 41009, Spain
Investigational Site Number : 7240003

Madrid, Madrid, Comunidad de, 28040, Spain
Investigational Site Number : 7240004

Madrid / Madrid, Madrid, Comunidad de, 28007, Spain
Investigational Site Number : 7240005

Murcia, 30120, Spain
Investigational Site Number : 7240006

Madrid, 28034, Spain